Laetsch, Theodore W. http://orcid.org/0000-0002-8497-3138
Maude, Shannon L.
Balduzzi, Adriana http://orcid.org/0000-0002-5879-0610
Rives, Susana
Bittencourt, Henrique
Boyer, Michael W.
Buechner, Jochen
De Moerloose, Barbara
Qayed, Muna
Phillips, Christine L.
Pulsipher, Michael A.
Hiramatsu, Hidefumi http://orcid.org/0000-0003-3136-5670
Tiwari, Ranjan
Grupp, Stephan A.
Article History
Received: 11 November 2021
Revised: 3 March 2022
Accepted: 16 March 2022
First Online: 14 April 2022
Competing interests
: TWL has received personal fees and nonfinancial support from Novartis, Cellectis, Bayer, Loxo Oncology, Eli Lilly, Deciphera, Jumo Health, and Y-mAbs Therapeutics; and research funding to his institution from Novartis, Pfizer, and Bayer. SLM has received clinical trial support from Novartis; and has served as a consultant or on advisory boards or study steering committees for Novartis, Kite, and Wugen. AB has received travel reimbursement and meeting support from Neovii and Medac; advisory board honorarium, speaker fees, and travel support from Novartis; and advisory board and speaker fees from Amgen. SR has received clinical trial support: consulting, advisory boards, travel reimbursement, and meeting support from Novartis, Shire/Servier, Cellectis, JazzPharma, Celgene, Kite/Gilead, and Amgen; and has served on a study steering committee for Novartis. HB has received consulting fees from Novartis Oncology, and personal fees and nonfinancial support from Jazz (outside the submitted work). MWB has received honoraria from Novartis. JB has received personal fees, advisory board/steering committee honoraria, and nonfinancial support from Novartis (during the conduct of the study); and advisory board honoraria from Pfizer, Kite, and Janssen (outside the submitted work). BDM has participated in an advisory board for Novartis; has received nonfinancial support from Articulate Science (during the conduct of the study); and has received nonfinancial support from Jazz Pharmaceuticals (outside the submitted work). MQ has received honoraria from Medexus, Jazz Pharmaceuticals, and Mesoblast, and has served as a consultant for Novartis. CLP has served as a member on the Board of Directors or Advisory Committees for Novartis and Incyte. MAP has received grants from Miltenyi and Adaptive; personal fees from Novartis, Adaptive, Mesoblast, Medexus, and Equillium. HH has received clinical trials support from Novartis. RT is an employee of Novartis. SAG has received grants and personal fees from Novartis, Jazz Pharmaceuticals, and CRISPR/Vertex; personal fees from Adaptimmune, TCR2 Therapeutics, Eureka Therapeutics, Cellectis, Roche, and Juno Therapeutics; and grants from Servier and Kite; and has been issued a patent for toxicity management for anti-tumor activity of CARs managed by the University of Pennsylvania.